share_log

HSBC Initiates Coverage On Teva Pharmaceutical Indus With Buy Rating, Announces Price Target of $13

Benzinga ·  Dec 18, 2023 08:07

HSBC analyst Rajesh Kumar initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment